Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
K.I. Halonen, V. Pettilä, A.K. Lepäniemi, E.A. Kemppainen, P.A. Puolakkainen, R.K. Haapiainen.
Multiple organ dysfunction asociated with severe acute pancreatitis.
Crit Care Med, 30 (2002), pp. 1274-1279
[2.]
J. Toouli, M. Brooke-Smith, C. Bassi, D. Carr-Locke, J. Telford, P. Freeny, et al.
Guidelines for the management of acute pancreatitis.
J Gastroenterol Hepatol, 17 (2002), pp. 15-39
[3.]
E. Domínguez, F. Carballo, M.J. García, J.M. De Diego, L. Rábago, M.A. Simón, et al.
Clinical usefulness of polymorphonuclear elastase in predicting the severity of acute pancreatitis: results of a multicentre study.
Br J Surg, 78 (1991), pp. 1230-1234
[4.]
J.A. Viedma, M. Pérez-Mateo, E. Domínguez, F. Carballo.
Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A.
Gut, 33 (1992), pp. 1264-1267
[5.]
J.P. Neoptolemos, E.A. Kemppainen, J.M. Mayer, J.M. Fitzpatrick, M.G.T. Raraty, J. Slavin, et al.
Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study.
Lancet, 355 (2000), pp. 1955-1960
[6.]
M.L. Kylanpää-Bäck, A. Takala, E. Kemppainem, P. Poulkkainen, R. Haapiainen, H. Repo.
Procalcitonin strip test in the early detection of severe acute pancreatitis.
Br J Surg, 88 (2001), pp. 222-227
[7.]
J.M. Mayer, M. Raraty, J. Slavin, E. Kemppainen, J. Fitspatrick, A. Hietaranta, et al.
Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis.
Br J Surg, 89 (2002), pp. 163-171
[8.]
R. Golub, F. Siddiqi, O. Pohl.
Role of antibiotics in acute pancreatitis: a meta-analysis.
J Gastrointest Sur, 2 (1998), pp. 496-593
[9.]
E.J.T. Luiten, W.C.J. Hop, J.F. Jange, H.A. Bruining.
Controled clinical trial of selective decontamination for the treatment of severe acute pancreatitis.
Ann Surg, 222 (1995), pp. 57-65
[10.]
M. Al-Omran, A. Groof, D. Wilke.
Enteral versus parenteral nutrition for acute pancreatitis (Cochrane Review).
[11.]
A. Oláh, A. Belágyi, M.E. Issekutz, E. Gamal, S. Bengmark.
Randomized clinical trial of specific lactobacilus and fibre supplement to early enteral nutrition in patients with acute pancreatitis.
B J Surg, 89 (2002), pp. 1103-1107
[12.]
A. Satoh, T. Miura, K. Satoh, A. Masamune, T. Yamagiwa, Y. Sakai, et al.
Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis.
Pancreas, 25 (2002), pp. 245-250
[13.]
W.E. Steinberg, S.E. Schlesselman.
Treatment of acute pancreatitis: comparison of animal and human studies.
Gastroenterology, 93 (1987), pp. 1420-1427
[14.]
A. Andriulli, G. Leandro, A. Niro, A. Mangia, V. Festa, G. Gambassi, et al.
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Gastrointest Endosc, 51 (2000), pp. 1-7
[15.]
A. Andriulli, G. Leandro, R. Clemente, V. Festa, N. Caruso, V. Arnese, et al.
Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis.
Aliment Pharmacol Ther, 12 (1998), pp. 237-245
[16.]
F. Carballo, E. Domínguez, L. Fernández, C. Martínez, A. García, J. De la Morena.
Is somatostatin useful in the treatment of acute pancreatitis?.
A meta-analysis. Digestion, 49 (1991), pp. 12-13
[17.]
C.J. McKay, F.J. Curran, C. Sharples, J.N. Baxter, C.W. Imrie.
Prospective placebo-controlled randomize trial of lexipafant in predicted severe acute pancreatitis.
Br J Surg, 84 (1997), pp. 1239-1243
[18.]
Group BAPS.
Early treatment with lexipafant, a platelet activating antagonist, reduces maortality in acute pancreatitis: a double blind, randomized, placebo controlled study.
Gastroenterology, 113 (1997), pp. A453
[19.]
C.D. Johnson, A.N. Kingsnorth, C.W. Imrie, M.J. McMahon, J.P. Neoptolemos, C. McKay, et al.
Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.
Gut, 48 (2001), pp. 62-69
[20.]
A.S. Paszkowski, Rau, J.M. Mayer, P. Moller, H.G. Beger.
Thepapeutic application of caspase 1/interleukin-1beta-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis.
Ann Surg, 235 (2002), pp. 68-76
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
